Pulsenmore Wins First U.S. Client Following FDA Clearance
Israeli company Pulsenmore secures its first U.S. client, the Center for Fetal Medicine in Los Angeles, following FDA clearance for its home pregnancy.
Jerusalem, 2 February, 2026 (TPS-IL) — Pulsenmore Ltd., an Israeli developer of home ultrasound technology, announced its first commercial engagement in the United States following FDA approval of its home pregnancy ultrasound product. The company said it signed a services agreement in late January with the Center for Fetal Medicine & Women’s Ultrasound in Los Angeles, California.
Under the agreement, the center will purchase Pulsenmore ES home ultrasound services, allowing patients to undergo remote prenatal monitoring and potentially reduce in-person diagnostic visits. The California-based center specializes in maternal-fetal medicine and high-risk pregnancies, managing about 1,500 pregnancies annually across two locations. Pulsenmore said the deal marks a key step in its U.S. market strategy.



























